Disclaimer
We’re actively expanding Guideline Genius to cover the full UKMLA content map. You may notice some conditions not uploaded yet, or articles that only include diagnosis and management for now. For updates, follow us on Instagram @guidelinegenius.
We openly welcome any feedback or suggestions through the anonymous feedback box at the bottom of every article and we’ll do our best to respond promptly.

Thank you for your support.
The Guideline Genius Team

Total Live Articles: 312

Oral Corticosteroid Tapering

NICE CKS Corticosteroids – oral. Last revised: Jul 2025.

NICE guideline [NG243] Adrenal insufficiency: identification and management. 1.9 Managing glucocorticoid withdrawal to prevent adrenal insufficiency. Published: Aug 2024.

Why Oral Corticosteroids Needs Tapering

Prolonged systemic corticosteroid therapy suppresses endogenous cortisol production through negative feedback on the hypothalamic–pituitary–adrenal axis:

  • Exogenous glucocorticoids (e.g. oral prednisolone) reduce ACTH secretion
  • This leads to reduced adrenal cortisol synthesis
  • Sudden withdrawal may result in inadequate cortisol availability, particularly during physiological stress

 

This can cause:

  • Adrenal insufficiency
  • Adrenal crisis in severe cases

See the Adrenal Insufficiency (Hypoadrenalism) article for more information.

Tapering is required for systemic corticosteroids, which includes oral, IV, IM routes.

In contrast, most locally administered corticosteroids (e.g. topical, inhaled, intranasal, intra-articular corticosteroids) do NOT require tapering, as systemic absorption is minimal and clinically significant HPA axis suppression is unlikely when used at standard doses.

What is Corticosteroid Tapering

Corticosteroid tapering refers to the gradual, stepwise reduction in corticosteroid dose over time, rather than abrupt cessation, following a period of systemic steroid therapy.

 

Aims of corticosteroid tapering:

  • Allow recovery of the hypothalamic–pituitary–adrenal axis (for endogenous ACTH secretion to recover and resume endogenous cortisol production)
  • Prevent adrenal insufficiency
  • Reduce the risk of disease flare or rebound inflammation

Who Requires Oral Corticosteroid Tapering

Tapering (gradual withdrawal) should be considered in those whose disease is unlikely to relapse AND meet ANY of the following:

  • Received corticosteroid treatment for >3-4 weeks
  • Received >40 mg of prednisolone (or equivalent) daily for >1 week
  • Recently received repeated courses of corticosteroids (esp. for >3 weeks) (a common scenario is acute asthma exacerbation)
  • Have been taking repeated evening doses of corticosteroids
  • Taken a short course of corticosteroids within 1 year of stopping long-term treatment

If none of the above applies, oral corticosteroids may be stopped abruptly in those whose disease is unlikely to relapse.

Tapering Regimen

A typical oral glucocorticoid tapering regimen follows the 2 main phases below:

Phase 1 Rapidly reduce the steroid dose to daily physiological dose

Physiological dose in >16 y/o:

  • Prednisolone 3-5 mg
  • Hydrocortisone 15-25 mg
  • Dexamethasone 0.5 mg

Physiological dose in <16 y/o: hydrocortisone 8 mg/m2

Phase 2 Once the patient in on a daily physiological dose, taper more gradually by alternate-day spacing (keeping the same daily doses but increasing the dosing interval):
  • Use the physiological dose every other day for 2 weeks, then
  • Use the physiological dose twice a week for 2 weeks, then
  • Stop completely

Note: Although NICE CKS and NICE guidance recommended the alternate-day dose spacing as corticosteroid tapering regimen, this approach is used less commonly in clinical practice.

It is more common to achieve tapering through small, incremental daily dose reductions.

In patients who have been taking oral glucocorticoids for >12 weeks, consider an even slower dose-tapering regimen (than what is outlined in the phase 2 row).

References

Share Your Feedback Below

UK medical guidelines made easy. From guidelines to genius in minutes!

Quick Links

Cookie Policy

Social Media

© 2026 GUIDELINE GENIUS LTD